Cancer Stage Shifting Initiative Program

Create a logic model of the Cancer stage shifting Initiative Program. Link provided https://shiftcancer.org.
The logic model should visually depict the inputs, activities, outputs, outcomes, and impact. It should also include the primary resources and all major activities necessary to implement the program. Use arrows to demonstrate the relationships between specific elements.

1.Cancer Stage Shifting Initiative program report https://shiftcancer.org/wp-content/uploads/2023/10/CSSI-Endpoints-Report-2023-FINAL.pdf
2.Logic Model Example https://ctb.ku.edu/en/table-of-contents/overview/models-for-community-health-and-development/logic-model-development/example

Identifying Stakeholders for the Cancer Stage Shifting Initiative Program
Category Stakeholders

1. Who is affected by the program? • Patients, primarily high-risk Asian Americans (Bengali, Chinese, Thai, and South Korean) aged 50 and above with a history of smoking.
   • Underserved communities, predominantly minority populations, are less likely to have access to lung cancer screenings and early diagnosis.
   • Caregivers, mostly the families of cancer patients, who support them during the treatment process.
   • Local communities, especially those engaged through educational outreach and community events.
2. Who is involved in program operations?
    The National Minority Quality Forum (NMQF): The organization managing the program.
    NYC Health and Hospitals: Partner healthcare system providing services.
    HAIR Wellness Warrior partners: Engaged in advocacy and awareness efforts.
    Healthcare professionals: Physicians, nurses, and cancer detection and treatment specialists.
3. Who will use evaluation results?  Funders: AstraZeneca and potential future funders assessing the impact of their contributions.
    Healthcare systems: NYC Health and Hospitals and other healthcare providers seeking to improve cancer care through early detection.
    Policy advocates: Individuals and organizations aiming to advance cancer and health equity policies.1
    Public health organizations: Using the data to improve cancer screening protocols and outcomes.2

Identifying the Key Stakeholders to Improve Credibility, Implementation, Advocacy, and Finding Decisions
Increase the credibility of our
evaluation Implement the interventions that
are central to this evaluation Advocate for changes to
institutionalize the evaluation
findings Fund or authorize the program
• Suneetha Natarajan, MD, Oncology Specialist: Located at NYC Health + Hospitals/Elmhurst
• Dr. Bernard Harris, CEO and managing partner at NMQF.  Dorothy Reynolds, community outreach specialist, HAIR Wellness Warrior.
 Faith Health Alliance Coordinators, NYC. o Dr. Yolanda Lawson, policy advocate at NMQF.
o Reverend Dr. Terris King, community health advocate at Faith Health Alliance.  AstraZeneca
 NYC Health and Hospitals

Developing a List of Stakeholder Questions
Stakeholder Questions
Healthcare providers  What are the most critical components of lung cancer screening that you believe this program should address?3
 How can we streamline the referral process to increase early-stage cancer detection?
 What resources and support do you need to reach high-risk patients effectively?3
 How will you utilize the results of this evaluation to improve early-stage cancer detection in your practice?
 Given the time and resources available, how much effort can your team contribute to ongoing program evaluations and improvements?
Community partners (Faith Health Alliance and HAIR Wellness Warrior)  What aspects of lung cancer awareness and prevention are most important to the communities you serve?
 How can we collaborate to ensure culturally sensitive outreach and education on lung cancer screening?
 What challenges do you foresee in increasing community engagement for cancer screenings?
 How can we ensure that our outreach efforts ethically address the program’s positive and negative impact on the communities you serve?
 What additional insights and data from the community would provide a more accurate and complete understanding of the program’s effectiveness?
Funders (AstraZeneca) What specific outcomes or data are most valuable to you when assessing the impact of this program?
How can we demonstrate the long-term sustainability of the initiative to secure continued funding?
Are there any additional areas or innovations you want to be integrated into future program phases?
What level of stakeholder engagement do you expect to see as part of our program’s evaluation and reporting process?
What metrics and outcomes from these evaluations will influence future funding decisions?3

Policymakers and Public Health Officials  What policy changes are crucial in enhancing lung cancer screening accessibility in underserved communities?
 How can the program’s evaluation results inform broader health strategies and funding allocations?
 How can you envision the integration of multi-cancer early detection (MCED) technologies into routine cancer care?
 How can we ensure that our evaluation reflects the ethical considerations of equity in cancer detection?